Table 1.

2007 Infectious Diseases Society of America/American Thoracic Society Guideline Recommendations for empirical therapy for community-acquired pneumonia

Inpatients, non-ICU treatment

A respiratory fluoroquinolonea

A nonantipseudomonal β-lactamb plus a macrolidec

Inpatients, ICU treatment

A nonantipseudomonal β-lactamb plus either azithromycin or a respiratory fluoroquinolonea

If Pseudomonas is a concern

An antipneumococcal, antipseudomonal β -lactamd plus either ciprofloxacin or levofloxacin

or

The above β-lactam plus an aminoglycosidee and azithromycin

or

The above β-lactam plus an aminoglycosidee and a respiratory fluoroquinolonea

ICU: intensive care unit

^aLevofloxacin, or moxifloxacin

^bCefotaxime, ceftriaxone, ampicillin/sulbactam, or ertapenem

^cAzithromycin, clarithromycin, or erythromycin

^dPiperacillin-tazobactam, cefepime, imipenem, or meropenem

^eAccording to Thai guidelines for the management of adults with community-acquired pneumonia, adding an aminoglycoside is optional. An aminoglycoside may be added to the initial antibiotic regimens only if multi-drug resistant Pseudomonas infection is suspected